Last reviewed · How we verify
Levovir (CLEVUDINE)
Levovir works by inhibiting viral DNA synthesis, specifically targeting the hepatitis B virus.
Levovir, also known as Clevudine, is a small molecule clevudine drug developed by an unknown original developer. It is currently owned by an unknown entity. Levovir is approved to treat Chronic type B viral hepatitis. The commercial status of Levovir is unknown, and it may be patented or generic. Key safety considerations are not specified.
At a glance
| Generic name | CLEVUDINE |
|---|---|
| Drug class | clevudine |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | discontinued |
Mechanism of action
Imagine your body's cells are like factories that make proteins. The hepatitis B virus takes over these factories and makes more viruses. Levovir stops the virus from making copies of itself by blocking the enzymes it needs to replicate.
Approved indications
- Chronic type B viral hepatitis
Common side effects
Key clinical trials
- 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases (EARLY_PHASE1)
- 18F-FMAU PET/CT in Imaging Patients With Advanced Cancers (NA)
- 18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer (PHASE1)
- PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer (NA)
- ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy (PHASE3)
- Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects (PHASE1)
- A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection (PHASE2)
- The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levovir CI brief — competitive landscape report
- Levovir updates RSS · CI watch RSS